For many years, the PSA blood test has been one of the main tools used to detect possible prostate cancer. If you have had a PSA test, you may have wondered what your results mean and whether screening can genuinely help detect cancer early.
The challenge with PSA screening is that your PSA level can provide useful information, but it does not always give a clear answer on its own. A raised PSA does not automatically mean you have cancer, while some cancers found through screening may never have caused problems during your lifetime.
The PLCO Trial was one of the largest studies designed to examine whether regular PSA screening could reduce deaths from prostate cancer. If you are considering PSA testing, the findings help explain why doctors now look at your age, risk factors, family history, PSA results, and overall health rather than relying on screening alone.
The results of the PLCO Trial continue to influence how your specialist approaches prostate cancer screening today. The study showed that decisions about PSA testing need to balance the potential benefit of finding important cancers early with the risks of overdiagnosis, unnecessary investigations, and treatment side effects.
What Was the PLCO Trial?
The PLCO Trial stands for the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. It was a large American research study designed to evaluate whether cancer screening could reduce deaths from several common cancers and help doctors identify disease at an earlier stage.
For prostate cancer, the trial examined whether regular PSA testing and digital rectal examinations could improve outcomes compared with usual medical care. If you were participating in the screening group, you would have received organised screening over a number of years, allowing researchers to compare your outcomes with those of men receiving standard care.
The study became one of the most influential trials in discussions about PSA screening because of its large size and long follow-up period. The findings continue to influence how your doctor discusses the potential benefits, limitations, and uncertainties of PSA testing when helping you make decisions about prostate cancer screening.
Why Was the PLCO Trial Needed?
Before the PLCO Trial, doctors knew that PSA testing could often detect prostate cancer at an earlier stage. However, if you were diagnosed through screening, it was not always clear whether finding cancer earlier would automatically improve your long-term survival or overall health outcomes.
One of the challenges was that some prostate cancers grow very slowly and may never cause symptoms during your lifetime. This meant that screening could identify cancers that might never have affected your health, while still leading to further tests, anxiety, and possible treatment.
Researchers wanted to understand whether detecting prostate cancer through PSA screening provided enough benefit to justify these potential disadvantages. The trial was designed to help doctors understand whether regular screening could reduce prostate cancer deaths and whether the benefits outweighed the possible risks for men like you.
How Does PSA Screening Work?
The PSA test is a simple blood test that measures prostate-specific antigen (PSA), a protein produced by cells within your prostate gland. If you have concerns about prostate cancer or urinary symptoms, your doctor may recommend a PSA test as part of your assessment.
A higher PSA level can sometimes indicate prostate cancer, but it is important to remember that your PSA can rise for several other reasons as well. Conditions such as an enlarged prostate, inflammation, infection, or even certain activities can affect your PSA result without cancer being present.
This means the PSA test is most useful when interpreted alongside your overall health information and other clinical findings rather than being used as a standalone result.
Clinical Tip: Prepare Properly Before a PSA Test
Before having a PSA test, ask your doctor whether anything could temporarily affect your result. NHS advice recommends avoiding activities that may temporarily affect PSA levels, such as ejaculation and vigorous exercise, before your test. You should also tell your doctor if you have had a recent urine infection or prostate procedure, as these factors may influence how your PSA result is interpreted.
What Did the PLCO Trial Compare?
The PLCO Trial compared men who were offered regular PSA screening with men who received usual medical care. If you were in the screening group, you would have been invited to undergo PSA testing at regular intervals rather than relying solely on routine healthcare visits or symptom-driven assessment.
The screening programme included PSA blood tests and digital rectal examinations, allowing researchers to evaluate whether organised screening could identify prostate cancer earlier and improve long-term outcomes. This gave investigators the opportunity to compare how screening affected the health of men over many years.
Researchers then followed participants to compare prostate cancer diagnoses, treatments, and deaths between the two groups. By tracking these outcomes over time, they aimed to determine whether regular screening provided meaningful benefits for men like you compared with standard care.
What Was the Main Finding of the PLCO Trial?
The main finding of the PLCO Trial was that organised PSA screening did not show a significant reduction in prostate cancer mortality when compared with usual medical care. If you read the results on their own, you might conclude that regular PSA screening did not provide a major survival benefit.
However, the findings are more complicated than they first appear. Many men in the usual-care group also had PSA tests outside the trial, which meant they were screened even though they were not part of the organised screening programme. If you compare two groups that both receive substantial PSA testing, it becomes much harder to see whether organised screening offers any additional advantage.
This overlap reduced the difference between the groups and made it more difficult for researchers to determine the true effect of screening. For this reason, when your specialist discusses the PLCO Trial with you, they will often explain its limitations and consider its findings alongside other major studies. This helps you gain a more balanced understanding of what PSA screening may and may not offer for your individual situation.
Evidence Note:
The PLCO prostate screening trial included 76,693 men aged 55 to 74 who were randomly assigned to organised screening or usual care. Men in the screening group were offered annual PSA testing for six years and digital rectal examination for four years. Extended follow-up continued to show no statistically significant reduction in prostate cancer mortality in the organised screening group compared with usual care. However, because PSA testing was common in the usual-care group, the PLCO Trial is better interpreted as showing no clear additional mortality benefit from the organised screening programme compared with existing PSA testing practices, rather than proving that PSA testing itself has no value.
PLCO Trial: Organised PSA Screening vs Usual Care Outcomes
| Finding | Organised screening | Usual care | What it means |
| PSA testing | Annual PSA offered for six years | Testing determined through usual care; opportunistic PSA testing was common | The two groups were less different than intended |
| Prostate cancer detection | More cancers diagnosed | Fewer cancers diagnosed | Organised screening increased detection, including detection of more lower-grade cancers |
| Prostate cancer deaths at extended follow-up | 333 of 38,340 | 352 of 38,343 | No statistically significant mortality reduction |
| Detection of lower-risk cancers | Higher | Lower | Screening increased detection of cancers that may have been less likely to cause harm |
| Main limitation | — | High use of PSA testing outside the assigned programme | Contamination made the effect of screening difficult to isolate |
Why Did PLCO and ERSPC Have Different Results?
The PLCO Trial and the ERSPC Trial were both major studies that examined PSA screening, but they were designed differently and took place in different healthcare environments. If you compare their findings, you may wonder why two large trials reached different conclusions about the benefits of prostate cancer screening.
The ERSPC Trial generally showed a reduction in prostate cancer deaths with PSA screening after longer follow-up, although concerns about overdiagnosis and unnecessary treatment still remained. If you read about PSA screening today, you will often find that the ERSPC findings are discussed alongside the PLCO results because both studies provide important evidence.
Several factors may explain why the outcomes differed. These include differences in how often participants were screened, how many men took part in screening, the healthcare systems involved, and the amount of PSA testing that occurred outside the studies. When your doctor discusses PSA screening with you, they will usually consider evidence from both trials to help you understand the potential benefits and limitations based on your individual risk factors and circumstances.
What Is the ERSPC Trial?
The ERSPC Trial, or European Randomised Study of Screening for Prostate Cancer, was one of the largest and most influential studies investigating PSA screening. If you are researching prostate cancer screening, you will often see the ERSPC Trial discussed alongside the PLCO Trial because both studies helped shape modern screening recommendations.
Unlike the PLCO Trial, which was conducted in the United States, the ERSPC Trial took place across several European countries and compared PSA screening with no organised screening programme. This allowed researchers to examine whether regular PSA testing could reduce the number of deaths caused by prostate cancer over time.
The study suggested that PSA screening could reduce prostate cancer mortality in some groups of men. However, it also showed that screening could increase the likelihood of diagnosing cancers that may never have caused symptoms or affected your health. This is why, when you discuss PSA testing with your doctor, the potential benefits of early detection are usually balanced against the risks of overdiagnosis and unnecessary treatment.
Research Insight:
At a median follow-up of 23 years, the ERSPC study reported that one prostate cancer death was prevented for every 456 men invited for screening. The long-term results support a mortality benefit, but they also reinforce the need for risk-based screening strategies that reduce overdiagnosis.
Why Was Contamination Important in PLCO?
One of the most important issues in the PLCO Trial was what researchers called contamination. If you are reading about the study today, this is one of the key reasons why the results must be interpreted carefully.
Contamination occurred when men in the control group, who were not assigned to the organised screening programme, still had PSA tests through their usual healthcare outside the trial. This meant that many participants who were supposed to represent non-screened care were actually receiving some degree of screening.
Because both groups underwent PSA testing, the difference between organised screening and usual care became much smaller. If you compare two groups that are both being screened to some extent, it becomes much harder to measure the true effect of the screening programme.
This made it more difficult for researchers to determine whether organised PSA screening provided additional benefits. As a result, when your specialist discusses the PLCO findings with you, they will often explain how contamination may have influenced the study outcomes and why the results should be considered alongside evidence from other major trials.
Did PLCO Show That PSA Testing Does Not Work?
No. The PLCO Trial does not mean that PSA testing has no value. If you read only the headline findings, you might assume that PSA screening is ineffective, but the study’s conclusions are more nuanced than that.
The trial highlighted how complex population-wide screening can be. While PSA testing can help identify prostate cancer earlier, it can also lead to overdiagnosis, additional investigations, and treatment of cancers that may never have affected your health. This means the benefits and disadvantages of screening are not always straightforward.
PSA testing can still be a useful tool when it is interpreted in the context of your individual circumstances. Your age, family history, symptoms, ethnic background, overall health, and PSA level can all influence how your doctor assesses your risk.
Today, PSA testing is often used as part of a more personalised approach rather than as a stand-alone screening tool. By considering your PSA result alongside other clinical information, your specialist can help you decide whether further investigation is likely to be beneficial for you.
What Is Overdiagnosis?
Overdiagnosis occurs when a test identifies a cancer that would never have caused symptoms or affected your lifespan. If you are diagnosed with one of these cancers, you may go through investigations and treatment for a condition that might never have become a problem during your lifetime.
This issue is particularly relevant in prostate cancer because some prostate tumours grow very slowly. While some cancers can be aggressive and require treatment, others may remain stable for many years and never affect your health or quality of life.
When a low-risk cancer is detected, it can lead to additional tests, ongoing monitoring, and understandable anxiety about your diagnosis. In some cases, you may also be offered treatments that carry risks and side effects, even though the cancer itself might never have caused harm.
This is one reason why your doctor considers more than just a PSA result when assessing your risk. Modern prostate cancer care aims to identify cancers that are likely to matter to you while reducing unnecessary diagnosis and treatment wherever possible.
Why Can PSA Screening Be Difficult to Interpret?
PSA screening can be difficult to interpret because a raised PSA level does not automatically mean you have prostate cancer. If your PSA result is higher than expected, it may indicate that further assessment is needed, but it does not provide a diagnosis on its own.
Your PSA level can increase for several reasons other than cancer. Benign prostate enlargement, infection, inflammation, recent medical procedures, and even some everyday factors can affect your PSA result. This means that a raised PSA can sometimes create uncertainty about what is causing the change.
Because of these limitations, your doctor will not usually make decisions based on your PSA result alone. Instead, your specialist will consider your age, symptoms, family history, examination findings, MRI results, and other relevant clinical information.
By looking at the complete picture, your healthcare team can better understand your individual level of risk and decide whether you need further investigations such as MRI, repeat PSA testing, or a prostate biopsy.
Many men with a raised PSA do not have prostate cancer. A raised result should therefore prompt appropriate assessment rather than being treated as a cancer diagnosis.
How Did PLCO Influence Modern PSA Testing?
The PLCO Trial encouraged doctors to move away from a uniform population-screening approach and from the assumption that every prostate cancer detected through screening should automatically be treated. If you are considering PSA testing today, your assessment is likely to be far more personalised than it would have been in the past.
The study highlighted the challenges of overdiagnosis and unnecessary treatment, helping doctors focus on identifying the men who are most likely to benefit from further investigation. Rather than relying only on PSA results, your specialist will consider your wider clinical picture when deciding whether further assessment is needed.
Modern prostate cancer assessment also uses additional tools to improve decision-making. Depending on your situation, you may be offered an MRI scan, a formal risk assessment, repeat PSA testing, or a targeted biopsy if further investigation is needed.
This more individualised approach aims to ensure that you receive the right investigations at the right time. By combining your PSA result with other clinical information, your doctor can make decisions that are more closely tailored to your personal level of risk and healthcare needs.
Why Is Personalised Assessment Important?
Every man’s risk of prostate cancer is different, which is why a personalised assessment is so important. Your doctor will consider factors specific to you rather than relying on a single test result to guide decisions.
- Individual Risk Factors: Age, family history, ethnicity, genetics, PSA trends, prostate size, and previous test results all influence your likelihood of having clinically significant disease.
- Context Matters: A PSA level concerning for one person may have a different significance when considered alongside your overall health and risk profile.
- Guiding Further Investigations: Personalised assessment helps your specialist decide if further tests like MRI, repeat PSA, or a biopsy are appropriate.
- Tailored Care: This approach helps ensure that decisions reflect your individual circumstances rather than following a one-size-fits-all pathway.
Overall, personalised assessment helps your doctor decide which investigations are appropriate while avoiding unnecessary procedures.
Does a Raised PSA Mean You Have Cancer?
A raised PSA result does not automatically mean that you have prostate cancer. If your PSA level is higher than expected, it simply means that your doctor may need more information to understand why the result has changed and whether further assessment is appropriate.
Many men with elevated PSA levels do not have clinically significant prostate cancer. Your PSA can increase because of benign prostate enlargement, inflammation, infection, recent procedures, or other non-cancerous conditions, which is why a single PSA result cannot confirm a diagnosis.
If your PSA level is raised, your doctor will consider your age, symptoms, family history, previous PSA results, and other risk factors before deciding what to do next. Depending on your individual circumstances, you may be advised to repeat your PSA test, undergo an MRI scan, or have further investigations.
The most important point is that a raised PSA is a signal that further assessment may be needed, not proof that you have cancer. By looking at your overall risk profile, your specialist can recommend the most appropriate next steps for you.
How Has MRI Changed PSA Assessment?
One of the biggest changes since the PLCO Trial began has been the increased use of prostate MRI in the diagnostic pathway. If you have a raised PSA level today, your doctor is often able to gather much more information before deciding whether further investigations are necessary.
MRI can provide detailed images of your prostate and help identify areas that appear suspicious for clinically significant cancer. NICE guidance recommends using risk assessment, MRI and other investigations alongside PSA results to guide decisions about biopsy and further management. This allows your specialist to assess your risk more accurately and determine whether a biopsy is likely to provide useful information.
In the past, a raised PSA result often led more directly to biopsy. Today, your PSA level is usually considered alongside your MRI findings, symptoms, family history, prostate size, and other clinical factors before a decision is made.
This more personalised approach helps ensure that you are not assessed on the basis of a single test alone. By combining your PSA result with MRI and other risk factors, your doctor can make more informed decisions about whether you need monitoring, further investigation, or a prostate biopsy.
How Does PSA Fit Into Modern Diagnosis?
Today, PSA remains an important part of prostate cancer assessment, but it is no longer used in isolation. If you have a PSA test, your result is usually considered as one piece of a much broader assessment rather than being the sole basis for decisions about your care.
Your doctor will often review your PSA level alongside imaging findings, examination results and your previous medical information. If you have already undergone a biopsy, those findings may also play an important role in understanding your overall risk.
This combined approach helps your specialist build a more complete picture of your prostate health. Rather than focusing only on whether your PSA is raised, your healthcare team can assess what that result means for you in the context of your individual circumstances.
By bringing together multiple sources of information, doctors can better identify men who are more likely to have clinically significant prostate cancer. This helps ensure that you receive appropriate investigations while reducing unnecessary tests and procedures whenever possible.
Why Is PSA Trend Important?
A single PSA result can provide useful information about your prostate health, but changes in your PSA level over time may provide useful additional context. If your PSA is changing from one test to the next, your doctor may want to understand why those changes are occurring rather than focusing only on a single result.
A changing or persistently raised PSA may prompt further assessment, particularly when combined with other concerning clinical findings. Looking at how your PSA changes over time can help your specialist gain a better understanding of your individual level of risk.
This is why your doctor may recommend repeat PSA testing rather than making decisions based on one isolated number. By reviewing your PSA trend alongside your age, symptoms, MRI findings, and overall health, your healthcare team can make more informed decisions about whether you need monitoring, further investigation, or treatment.
What Did PLCO Teach About Screening Benefits?
The PLCO Trial highlighted that the benefits of prostate cancer screening must always be weighed against the potential disadvantages. If you are considering PSA screening, it is important to understand that screening is not simply about finding more cancers, but about identifying the cancers that are most likely to affect your health.
Detecting cancer earlier does not automatically mean that you will live longer or benefit from treatment. Some prostate cancers grow so slowly that they may never cause symptoms or problems during your lifetime, while others are more aggressive and may benefit from earlier detection and management.
The trial helped show that the value of screening depends on finding cancers where early action can make a meaningful difference for you. This is why your doctor will consider your age, overall health, family history, PSA results, and other risk factors when discussing whether screening or further investigation is appropriate.
Today, screening decisions are increasingly personalised. By assessing your individual level of risk, your specialist can help you understand the potential benefits and limitations of PSA testing and decide what approach is most suitable for you.
What Did PLCO Teach About Screening Risks?
The PLCO Trial highlighted some of the potential risks associated with prostate cancer screening, particularly the possibility of unnecessary diagnosis and treatment. If you undergo PSA screening, there is a chance that a test may identify a cancer that would never have caused symptoms or affected your lifespan.
When this happens, you may be offered additional investigations such as MRI scans or biopsies, which can create anxiety and uncertainty. In some cases, you may also receive treatment for a cancer that might never have caused harm, exposing you to possible side effects without providing a clear benefit.
The trial reinforced the importance of helping you understand both the benefits and the potential disadvantages of screening before decisions are made. Rather than assuming that every detected cancer requires immediate treatment, modern prostate cancer care focuses on assessing your individual level of risk and determining which cancers are most likely to require intervention.
This more balanced approach aims to ensure that you receive appropriate investigations and treatment when needed while avoiding unnecessary procedures whenever possible.
Why Does Shared Decision-Making Matter?
The PLCO Trial helped change conversations between doctors and patients by showing that prostate cancer screening decisions are not always straightforward. If you are considering PSA testing, there may not be a single right answer that applies to everyone, which is why your individual circumstances are so important.
Some men place a high value on the possibility of detecting cancer at an earlier stage, while others may be more concerned about the risks of unnecessary investigations, overdiagnosis, or treatment side effects. The balance between these benefits and risks can be different for you than it is for someone else.
Shared decision-making allows you and your doctor to discuss your personal risk factors, including your age, family history, ethnicity, symptoms, and overall health. It also gives you the opportunity to ask questions, understand the possible outcomes, and express what matters most to you.
By working together, you and your specialist can make a decision that reflects both the available medical evidence and your personal preferences. This helps ensure that any choice about PSA screening is tailored to your individual needs and goals.
How Does Family History Affect PSA Decisions?
Family history is one of the factors that may influence your risk of developing prostate cancer. If you have a close relative, such as a father, brother, or son, who has been diagnosed with prostate cancer, your risk may be different from that of someone without a family history of the disease.
When your doctor assesses whether PSA testing is appropriate, your family history can provide important information about your individual risk profile. A strong family history may influence when you begin discussing PSA testing, how closely your PSA levels are monitored, and whether additional investigations should be considered.
By taking your family history into account alongside other clinical information, your healthcare team can make more personalised recommendations about PSA testing and any further assessment that may be appropriate for you.
How Does Age Influence PSA Screening?
Age is an important factor when interpreting your PSA results and deciding whether prostate cancer screening is likely to be beneficial for you. As you get older, both your risk of prostate cancer and the likelihood of other health conditions can change, which may influence how screening results are assessed.
The potential benefits and disadvantages of PSA screening can vary depending on your expected lifespan, general health, and individual risk of developing clinically significant prostate cancer. For some men, early detection may provide important opportunities for treatment, while for others the risks of overdiagnosis and unnecessary intervention may be more relevant.
When your doctor reviews your PSA result, they will usually consider your age alongside your family history, symptoms, PSA trend, examination findings, and any MRI results. Looking at these factors together helps your specialist understand what your PSA level means in the context of your overall health.
This is why PSA screening decisions are often personalised rather than based on a single age cut-off. By considering your individual circumstances, your doctor can help you decide whether screening or further investigation is appropriate for you.
Why Is Over-Treatment a Concern?
Treatment for prostate cancer can be highly effective and, in many cases, can provide excellent long-term cancer control. However, if you undergo treatment for a cancer that was unlikely to cause harm, you may be exposed to side effects without receiving a meaningful health benefit.
Depending on the treatment you receive, there can be important effects on your quality of life. Surgery may affect your urinary continence and sexual function, while radiotherapy can cause urinary symptoms, bowel changes, or changes in sexual function. These risks are often an important part of the decision-making process for you and your specialist.
The challenge highlighted by studies such as the PLCO Trial is making sure that treatment is directed towards the men who are most likely to benefit from it. If your cancer is clinically significant, treatment may be the most appropriate option. If your cancer is low risk, monitoring may sometimes be considered instead.
This is why your doctor will assess your cancer characteristics, overall health, personal priorities, and risk factors before recommending treatment. The goal is to ensure that any treatment you receive is more likely to help you than harm you.
How Has Diagnosis Improved Since PLCO?
Since the PLCO Trial began, prostate cancer diagnosis has changed significantly. If you are being assessed for possible prostate cancer today, you are likely to benefit from diagnostic tools and techniques that were not widely available when the study first started.
Advances such as multiparametric MRI, targeted biopsy, and improved risk assessment tools now provide your specialist with much more information before recommending further investigation or treatment. These developments help your doctor understand not only whether cancer may be present, but also how likely it is to be clinically significant.
Instead of relying heavily on PSA testing alone, your assessment can now include MRI findings, PSA trends, prostate size, family history, symptoms, and other important factors. This allows your healthcare team to make decisions that are more personalised and based on a clearer understanding of your individual risk.
The overall aim of these advances is to make prostate cancer detection more accurate while reducing unnecessary procedures. By improving how your risk is assessed, modern diagnostic pathways help ensure that you receive the most appropriate investigation and treatment for your situation.
Does PLCO Mean Men Should Avoid PSA Testing?
No. The PLCO Trial does not mean that you should avoid PSA testing or that PSA screening has no value. If you are considering a PSA test, the study’s findings should be viewed as part of a broader discussion about the potential benefits and limitations of screening.
The trial highlighted that PSA screening is more complex than simply testing everyone and treating every cancer that is found. Whether PSA testing is appropriate depends on your individual level of risk, health circumstances and personal preferences.
Your doctor can help you understand what a PSA test may and may not tell you. By discussing your individual level of risk, you can gain a clearer understanding of the possible outcomes of testing and whether further investigations might be needed if your PSA level is raised.
Rather than suggesting that men should avoid PSA testing, the PLCO Trial reinforced the importance of a personalised approach. A discussion with your specialist can help you decide whether PSA testing is appropriate for you and how the results would be used to guide your care.
What Happens After a Raised PSA Result?
A raised PSA result usually leads to further assessment rather than an immediate diagnosis of prostate cancer. If your PSA level is higher than expected, your doctor will want to understand what may be causing the result before making any conclusions about your prostate health.
Your specialist may review your previous PSA results, look at how your PSA has changed over time, perform additional examinations, or arrange further investigations such as a prostate MRI. Depending on your individual circumstances, you may also be advised to have repeat PSA testing or a prostate biopsy to gather more information.
If you need specialist advice regarding a raised PSA evaluation, your assessment should consider much more than your PSA level alone. Your doctor will usually take into account your age, family history, symptoms, examination findings, MRI results, and other relevant risk factors.
By looking at your complete clinical picture, your healthcare team can develop a more accurate understanding of your prostate cancer risk and recommend the most appropriate next steps for you.
How PLCO Influenced Future Research
The PLCO Trial encouraged researchers to look beyond simple PSA screening and investigate better ways of identifying clinically important prostate cancers. If you are being assessed today, many of the advances used in modern prostate cancer care have been influenced by questions raised through studies such as PLCO.
Following the trial, researchers explored new approaches including multiparametric MRI, improved biomarkers, genetic testing, risk calculators, and more personalised screening strategies. These developments have helped doctors gain a better understanding of which men are most likely to benefit from further investigation and treatment.
Rather than relying heavily on a single PSA result, your specialist can now use multiple sources of information to assess your individual level of risk. This allows your care to be tailored more closely to your personal circumstances and clinical findings.
The overall goal remains the same: to identify the cancers that are most likely to affect your health while reducing unnecessary investigations, overdiagnosis, and treatment. By improving how risk is assessed, modern research aims to ensure that you receive the right care at the right time.
What Questions Should You Ask Your Doctor?
If you are considering PSA testing, it is important to understand why the test has been recommended and what the results could mean for you. Asking questions can help you feel more informed and ensure that you understand how PSA testing fits into your overall prostate health assessment.
You may want to ask your doctor what your PSA result means, how your age affects your risk, and whether your family history or symptoms influence the need for further investigation. You can also ask how your previous PSA results compare with your current level and whether any changes over time are significant.
If additional tests may be needed, you can ask whether an MRI, repeat PSA test, or biopsy could be recommended and how those results might influence your care. Understanding the possible next steps can help you prepare for different outcomes and make informed decisions.
By having an open discussion with your specialist, you can gain a clearer understanding of your personal risk and the purpose of testing. This allows you to make decisions about PSA screening and further assessment with greater confidence.
What Is the Main Lesson From the PLCO Trial?
The PLCO Trial showed that prostate cancer screening is more complex than simply testing everyone on a regular basis. If you are considering PSA testing, the study highlights why screening decisions should be based on your individual circumstances rather than a one-size-fits-all approach.
Its findings emphasised the importance of balancing the potential benefits of early cancer detection with the risks of overdiagnosis, unnecessary investigations, and treatment that may not always provide meaningful benefit. While screening can help identify important cancers, it can also lead to the detection of cancers that might never have affected your health.
Today, your PSA test is usually considered as part of a wider assessment that combines clinical findings with additional investigations where appropriate. This allows your doctor to develop a more complete understanding of your individual level of risk before recommending further investigations.
The most important lesson from the PLCO Trial is that prostate cancer detection should focus on finding the cancers that are most likely to matter to you while helping you avoid unnecessary procedures whenever possible. By using a personalised approach, your specialist can help ensure that any testing or treatment is more closely matched to your needs and overall health.
Myth vs Fact
| Myth | Fact |
| PLCO proved PSA testing is useless. | PLCO showed no mortality benefit for organised screening compared with usual care, but many control-group men also had PSA tests. |
| A raised PSA means prostate cancer. | PSA can rise because of benign prostate enlargement, infection, inflammation, recent ejaculation, certain activities or other factors. |
| A normal PSA does not completely rule out prostate cancer. | Some men with prostate cancer can have PSA levels that are not clearly raised. |
| Screening is always beneficial. | Screening can detect important cancers early, but it can also cause overdiagnosis and unnecessary treatment. |
| Every prostate cancer found by PSA needs treatment. | Some low-risk cancers can be monitored safely with active surveillance. |
| The UK offers routine PSA screening to all men. | The UK does not recommend population-wide prostate cancer screening. Men at higher genetic risk may discuss PSA testing approaches with their healthcare professional. |
Key Takeaways:
- The PLCO Trial examined whether organised PSA screening and digital rectal examination reduced prostate cancer deaths.
- The trial did not show a significant mortality reduction for organised screening compared with usual care.
- Interpretation is complicated because many men in the usual-care group also had PSA testing outside the trial.
- PLCO does not prove PSA testing has no value; it shows that screening decisions are complex.
- ERSPC found a prostate cancer mortality reduction with PSA screening after long-term follow-up, but overdiagnosis remained a concern.
- PSA should be interpreted alongside age, symptoms, family history, ethnicity, PSA trend, MRI findings and overall health.
- In the UK, population-wide prostate screening is not recommended, but targeted PSA testing approaches may be considered for some men at higher risk, including those with relevant genetic risk factors such as BRCA2 variants.
- A raised PSA is not a cancer diagnosis; it is a reason for careful assessment.
FAQs:
1. What was the main purpose of the PLCO Trial?
The PLCO Trial was designed to determine whether regular PSA screening could reduce deaths from prostate cancer. Researchers compared men who received organised screening with those who received usual medical care. The aim was to understand both the benefits and limitations of routine PSA testing.
2. What did the PLCO Trial find about PSA screening?
The trial found that organised PSA screening was not associated with a statistically significant reduction in prostate cancer mortality compared with usual care. However, many men in the usual-care group also underwent PSA testing outside the study. This made it more difficult to determine the true impact of organised screening alone.
3. Does the PLCO Trial mean PSA testing is not useful?
No, the PLCO Trial does not suggest that PSA testing has no value. PSA remains an important tool for assessing prostate cancer risk when interpreted alongside other clinical information. The study highlighted the need for a more personalised approach rather than relying on PSA results alone.
4. Why are the PLCO and ERSPC trials often compared?
Both studies examined whether PSA screening could reduce deaths from prostate cancer, but they used different study designs and were conducted in different healthcare settings. The ERSPC Trial reported a reduction in prostate cancer mortality with screening, while PLCO did not show the same result. Together, they provide valuable evidence about the benefits and limitations of prostate cancer screening.
5. What is overdiagnosis in prostate cancer screening?
Overdiagnosis occurs when screening identifies a prostate cancer that would never have caused symptoms or affected your lifespan. Although the cancer is real, it may not have required treatment during your lifetime. This can lead to unnecessary investigations, anxiety and treatments that may have side effects.
6. Does a raised PSA level mean you have prostate cancer?
No, a raised PSA level does not automatically mean you have prostate cancer. PSA can increase because of benign prostate enlargement, inflammation, infection and other non-cancerous conditions. Further assessment is usually needed to understand what is causing the result.
7. How has MRI changed the way raised PSA results are investigated?
MRI provides detailed images of the prostate and helps identify areas that may be suspicious for clinically significant cancer. This allows doctors to gather more information before deciding whether a biopsy is necessary. As a result, prostate cancer assessment has become more targeted and personalised.
8. Why is personalised PSA assessment important?
Every man has a different level of prostate cancer risk based on factors such as age, family history, ethnicity and overall health. Looking at these factors alongside PSA results helps doctors make more informed decisions about further investigations. This approach reduces unnecessary procedures while focusing on men who are most likely to benefit from additional testing.
9. What happens after a raised PSA result?
A raised PSA result usually leads to further assessment rather than an immediate cancer diagnosis. Your doctor may review previous PSA results, arrange an MRI scan, repeat the blood test or recommend a biopsy depending on your individual circumstances. The next step will depend on your overall risk profile and clinical findings.
10. What is the main lesson from the PLCO Trial?
The PLCO Trial showed that prostate cancer screening is more complex than simply testing everyone regularly. Its findings highlighted the importance of balancing early cancer detection with the risks of overdiagnosis and unnecessary treatment. Today, PSA testing is generally used as part of a broader, personalised assessment rather than as a standalone screening tool.
Final Thoughts: What the PLCO Trial Still Teaches Us Today
The PLCO Trial remains one of the most important studies in the history of prostate cancer screening because it highlighted both the potential value and the limitations of PSA testing. Rather than showing that PSA screening is ineffective, the study demonstrated how complex screening decisions can be and why a single test result should never be viewed in isolation. Its findings encouraged doctors to look beyond routine screening alone and consider each person’s individual circumstances when assessing prostate cancer risk. If you are considering a raised PSA evaluation and would like specialist advice, you can contact us to discuss your options and arrange a consultation tailored to your individual needs.
References:
- Andriole, G.L., Crawford, E.D., Grubb, R.L., et al. (2012) ‘Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up’, Journal of the National Cancer Institute, 104(2), pp.125–132. Available at: https://pubmed.ncbi.nlm.nih.gov/22228146/
- Tsodikov, A., Gulati, R., Heijnsdijk, E.A.M., et al. (2017) ‘Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials’, Annals of Internal Medicine, 167(7), pp.449–455. Available at: https://pubmed.ncbi.nlm.nih.gov/28869989/
- Gulati, R., Gore, J.L., Etzioni, R., et al. (2012) ‘The Impact of PLCO Control Arm Contamination on Perceived PSA Screening Efficacy’, Cancer Causes & Control, 23(6), pp.827–835. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC3556907/
- Gulati, R. and Albertsen, P.C. (2017) ‘Insights from the PLCO Trial About Prostate Cancer Screening’, Cancer, 123(4), pp.546–548. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC5293617/
- National Institute for Health and Care Excellence (NICE) (2019, updated 2025) Prostate cancer: diagnosis and management (NG131). Available at: https://www.nice.org.uk/guidance/ng131
- UK National Screening Committee (UK NSC) (n.d.) The UK NSC recommendation on prostate cancer screening. Available at: https://view-health-screening-recommendations.service.gov.uk/prostate-cancer/
- NHS (n.d.) PSA test. Available at: https://www.nhs.uk/tests-and-treatments/psa-test/